ESTRELLA IMMUNOPHARMA, INC. Increase (Decrease) in Prepaid Expense
ESTRELLA IMMUNOPHARMA, INC. (ESLA) reported Increase (Decrease) in Prepaid Expense of $267.34 thousand for the 9-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2024-05-15
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in prepaid expense for the quarter ending 2024-03-31 was $4.86K, a 88.11% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in prepaid expense for the quarter ending 2023-06-30 was $42.17K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in prepaid expense for the quarter ending 2023-03-31 was $40.88K.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in prepaid expense for the quarter ending 2022-12-31 was -$75.38K, a 158.34% decline year-over-year.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in prepaid expense for fiscal 2022 was -$125.54K, a 191.52% decline from fiscal 2021.
- ESTRELLA IMMUNOPHARMA, INC. increase (decrease) in prepaid expense for fiscal 2021 was $137.17K.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $4.86K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15 | $267.34K 10-Q · filed 2024-05-15 | ||
| 2023-12-31 | $262.48K 10-Q · filed 2024-02-14 | |||
| 2023-06-30 | $42.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $83.05K 10-Q · filed 2023-08-01 | $7.67K derived: sum of 3 quarters · filed 2023-08-01 | $54.13K derived: sum of 4 quarters · filed 2023-08-01 |
| 2023-03-31 | $40.88K 10-Q · filed 2023-05-18 | -$34.50K derived: sum of 2 quarters · filed 2023-05-18 | $50.00K 10-Q · filed 2024-05-15 | -$53.91K derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-12-31 | -$75.38K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$28.91K derived: sum of 2 quarters · filed 2023-03-14 | -$94.79K derived: sum of 3 quarters · filed 2023-08-01 | -$125.54K 10-K · filed 2023-03-14 |
| 2022-09-30 | $46.46K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$19.41K derived: sum of 2 quarters · filed 2023-08-01 | -$50.16K 10-Q · filed 2022-11-14 | $79.03K derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-06-30 | -$65.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | -$96.63K 10-Q · filed 2023-08-01 | $32.58K derived: sum of 3 quarters · filed 2023-08-01 | $38.04K derived: sum of 4 quarters · filed 2023-08-01 |
| 2022-03-31 | -$30.75K 10-Q · filed 2023-05-18 | $98.45K derived: sum of 2 quarters · filed 2023-05-18 | $103.92K derived: sum of 3 quarters · filed 2023-05-18 | |
| 2021-12-31 | $129.20K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $134.67K derived: sum of 2 quarters · filed 2023-03-14 | $137.17K 10-K · filed 2023-03-14 | |
| 2021-09-30 | $5.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $7.97K 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $2.50K 10-Q · filed 2022-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |